araag2/HINT huggingface dataset:
Clinical trial NCT02936206 (phase 1, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: fulvestrant, tamoxifen
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H], OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
Reason stopped: 
    low accrual rate
  
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent prior to beginning specific protocol procedures, including
             expected cooperation of the patients for the study treatment regimen and follow-up,
             must be obtained and documented according to the local regulatory requirements

          -  Adult women greater than 18 years old

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

          -  New diagnosis of invasive cyclin D1 +, ER+, PR +/-, Her2- breast cancer

               -  Cyclin D1 positive as defined as a total immunohistochemical score of 5 or
                  greater

               -  Hormone receptor positive as defined as ≥ 10% positive stained cells

               -  HER2-normal (IHC score 0-1 or FISH negative [in-situ hybridization (ISH) ratio <=
                  2.0 status])

          -  Tumor size at least 5 mm with planned primary surgery at Mount Sinai

          -  A negative urine dipstick pregnancy test

        Exclusion Criteria:

          -  Estrogen receptor negative invasive breast carcinoma as defined as less than 10%
             stained cells

          -  Prior antiestrogen therapy

          -  Tumor size less than 5 mm

          -  Prior diagnosis of thrombosis or known hypercoagulable state

          -  Known history of bleeding diathesis

          -  Known liver disease

          -  Prior treatment with neoadjuvant therapy

          -  Inflammatory breast cancer defined as clinically significant erythema of the breast
             and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau
             d'orange without erythema).

          -  Current severe or uncontrolled systemic disease

          -  Pregnancy or lactation period. Patients of childbearing potential must implement
             adequate non-hormonal contraceptive measures (barrier methods, intrauterine
             contraceptive devices) during study treatment.

          -  Prior malignancy (including invasive or ductal in-situ breast cancer) within 5 years
             prior to randomization, except curatively treated basal cell carcinoma of the skin and
             carcinoma in situ of the cervix.
Clinical trial NCT02940002 (phase 1, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: bay1003803, clobetasol propionate, betamethasone/calcipotriene
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female (non-childbearing potential) volunteer with stable plaque-type
             psoriasis, but otherwise healthy

          -  Age: 18-64 years

        Exclusion Criteria:

          -  Severe disease within the last 4 weeks prior to the first study drug administration as
             determined by the investigator

          -  Any topical antipsoriatics on plaques potentially to be treated in this trial
             (including corticosteroids, vitamin D analogues, immunomodulators, retinoids,
             dithranol and tar, except for salicylic acid (Pretreatment) in the 4 weeks before
             first treatment and/or planned during the trial, except for allowed topical treatment
             on the face, ears and scalp

          -  Systemic treatment depending on kind of treatment within 4 weeks and 6 months prior
             and/or planned during the trial

          -  Treatment with concomitant medication that may affect and provoke or aggravate
             psoriasis, e.g. antimalarial drugs, lithium, beta-blockers or
             angiotensin-converting-enzyme inhibitors (AEC inhibitors) unless on a stable dose for
             3 months before study medication initiation

          -  Clinico-chemical parameters of clinically significant deviation
Clinical trial NCT02956538 (early phase 1, status: unknown status)
Conditions: crohn disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: thalidomide, placebo(for thalidomide)
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18-50 years old

          -  Diagnosis of patients with CD

          -  Disease in the activity: CDA Ⅰ > 150 points, endoscopic see active lesions

          -  Refractory: immunosuppressive drugs or biological agents which are used in current
             treatment is invalid and/or intolerance

        Exclusion Criteria:

          -  Fiber stenosis caused by gastrointestinal obstruction symptoms

          -  Fistula exclude anal fistula

          -  Pregnancy or lactation

          -  Period of women have fertility program during the study

          -  Treatment not foot eight weeks after last IFX

          -  Central or peripheral nerve disease

          -  Abnormal in liver and renal function

          -  Heart function failure

          -  Malignant tumor

          -  Active tuberculosis
Clinical trial NCT02958982 (phase 1/phase 2, status: terminated)
Conditions: healthy volunteers, asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: rp3128, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    significant recruitment delay in poc part
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male and non-childbearing female subjects (SAD/MAD) and male and non-childbearing
             female patients with mild asthma;

          -  Healthy subjects as determined by past medical history, vitals, physical examination
             and 12-lead ECG, clinical laboratory tests.

          -  Body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive, weight ≥50 kg;

          -  Non-smokers or ex-smokers

          -  Willingness to adhere to the protocol requirements as evidenced by the informed
             consent form (ICF) duly read, signed and dated by the subject; able to comply with
             protocol requirements and or study procedure;

          -  Negative screen for drugs of abuse and alcohol at screening and on admission.

          -  Male subjects should agree not to donate sperm for 3 months post dose; and

          -  Female partners (of child bearing potential) of male subjects should use 2 methods of
             highly effective contraception for 3 months post last

        Additionally for POC

          -  Pre- bronchodilator Forced expiratory volume in 1 sec( FEV1) of > 70% (adjusted for
             age, sex and race)

          -  Steroid naïve subjects with history of mild asthma that satisfy the Global Initiative
             for Asthma (GINA) definition of asthma, but otherwise healthy.

        Exclusion Criteria:

          -  Subjects with evidence or history of clinically significant medical history.

          -  History of tuberculosis (TB) and/or a positive Tuberculin Skin Test and/or
             QuantiFeron- TB®-Gold test.

          -  Use of any immunotherapy within 3 months prior to screening.

          -  History of serious adverse reaction, severe hypersensitivity or allergy to any
             drug/drug substance (except house dust mite, pollen allergens or cat dander allergy in
             asthmatics) or in any other circumstance (e.g. anaphylaxis);

          -  Abnormal liver function

          -  Positive screen on hepatitis-B surface antigen (HBsAg), antibodies to the hepatitis C
             (HCV) or antibodies to the human immunodeficiency virus (HIV) 1,2;
Clinical trial NCT02959619 (phase 1, status: unknown status)
Conditions: solid tumor, non-small cell lung cancer metastatic
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: ensartinib
SMILES: C[C@@H](OC1=CC(=NN=C1N)C(=O)NC1=CC=C(C=C1)C(=O)N1CCN(C)CC1)C1=C(Cl)C=CC(F)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy

          -  For the expanded cohort portion of the study, patients must have NSCLC with ALK
             genomic alterations positive by FISH or IHC

          -  Eastern Cooperative Group ECOG) Performance Status score of 0 or 1

          -  Adequate organ system function

          -  Male patients willing to use adequate contraceptive measures; female patients who are
             not of child-bearing potential, and female patients of child-bearing potential who
             agree to use adequate contraceptive measures

          -  Measurable disease per RECIST

          -  Willingness and ability to comply with the trial and follow-up procedures

          -  Written informed consents are required to indicate that the patients are aware of the
             investigational nature of the study

        Exclusion Criteria:

          -  Current use of anticancer therapy.

          -  Use of an investigational drug within 14 days or 5 half-lives (whichever is shorter)
             prior to the first dose of ensartinib

          -  Any major surgery, radiotherapy, or immunotherapy within the last 21 days.

          -  Chemotherapy regimens with delayed toxicity within the last 4 weeks.

          -  Chemotherapy regimens given continuously or on a weekly basis with limited potential
             for delayed toxicity within the last 2 weeks.

          -  Prior stem cell transplant

          -  Patients with a known allergy or delayed hypersensitivity reaction to drugs chemically
             related to ensartinib or to the active ingredient of ensartinib

          -  Prior use of ALK TKIs with the exception of crizotinib

          -  Primary CNS tumors or meningeal metastasis

          -  Pregnant or breastfeeding female

          -  Presence of active gastrointestinal (GI) disease or other condition that will
             interfere significantly with the absorption, distribution, metabolism, or excretion of
             ensartinib

          -  Clinically significant cardiovascular disease.

          -  Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol

          -  Concurrent condition evaluated by investigator would jeopardize compliance with the
             protocol or would impart excessive risk associated with study participation that would
             make it inappropriate for the patient to be enrolled

          -  Inability or unwillingness to comply with study and/or follow-up procedures outlined
             in the protocol
Clinical trial NCT02963376 (phase 1, status: completed)
Conditions: ischemic stroke
ICD codes: I25.5, H47.013, H93.013, G45.9, H47.011, H47.012, H47.019
Drugs: 0.05 ml/kg ddfpe, 0.05 ml/kg placebo, 0.10 ml/kg ddfpe, 0.10 ml/kg placebo, 0.17 ml/kg ddfpe, 0.17 ml/kg placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Ages 18-80 years

          -  Diagnosis of AIS

          -  Body weight ≥ 45 kg

          -  NIHSS between 2 and 20

          -  Patient or legal authorized representative (LAR) must be willing and able to
             understand the study and provide written informed consent

        Exclusion Criteria:

        Currently pregnant or breastfeeding

          -  History of significantly impaired renal or hepatic function

          -  Hemorrhage or hemorrhagic stroke on CT scan

          -  Prior stroke, intracranial surgery, or major head trauma within three months prior to
             enrollment

          -  Pre-stroke modified Rankin Scale (mRS) ≥ 2

          -  Myocardial infarction within six (6) months prior to enrollment

          -  Unstable angina, New York Heart Association (NYHA) Class II or greater congestive
             heart failure

          -  Uncontrolled hypertension (SBP > 180 and/or diastolic blood pressure (DBP) > 110 mmHg)

          -  Known long QT syndrome or QTc > 450 milliseconds (ms) in males and > 470 ms in females

          -  Uncontrolled arrhythmia or history of clinically significant arrhythmia within the
             past six (6) months (except atrial fibrillation)

          -  Clinically significant chronic obstructive pulmonary disease (COPD) or other pulmonary
             condition that is not controlled by medication or requires oxygen frequently or
             continuously

          -  Pneumonia, bronchitis, or other acute respiratory disease

          -  Current anticoagulant therapy except for antiplatelet therapy (aspirin, NSAIDs) and
             prophylactic doses of low molecular weight heparin to prevent deep vein thrombosis.
             Note: tPA administered as part of subjects' therapy for AIS is allowed.

          -  History of allergic reaction attributed to compounds of similar chemical composition
             to DDFPe (see Investigator's Brochure).

          -  Subject has received any investigational drug within thirty (30) days prior to
             enrollment into the study

          -  Inability to comply with the study procedures

          -  History or evidence of any other clinically significant condition that, in the opinion
             of the investigator, might pose a safety risk to subjects or interfere with study
             procedures, evaluation, or completion
Clinical trial NCT02964377 (phase 1/phase 2, status: completed)
Conditions: duchenne muscular dystrophy
ICD codes: G71.01
Drugs: (+)- epicatechin
SMILES: O[C@@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male

          -  Age 8 years to 17 years

          -  Non-Ambulatory (unable to complete 10m run/walk under 10s)

          -  Weight </=100Kg

          -  Diagnosis of DMD confirmed by at least one the following:

               -  Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin
                  deficiency, and clinical picture consistent with typical DMD, or

               -  Gene deletions test positive (missing one or more exons) of the dystrophin gene,
                  where reading frame can be predicted as 'out-of-frame', and clinical picture
                  consistent with typical DMD, or

               -  Complete dystrophin gene sequencing showing an alteration (point mutation,
                  duplication, or other mutation resulting in a stop codon mutation) that can be
                  definitely associated with DMD, with a typical clinical picture of DMD, or

               -  Positive family history of DMD confirmed by one of the criteria listed above in a
                  sibling or maternal uncle, and clinical picture typical of DMD.

          -  Cardiac ejection fraction >55% on echocardiogram

          -  Use of nutritional, herbal and antioxidant supplements taken with the intent of
             maintaining or improving skeletal muscle strength or functional mobility has been
             discontinued at least 4 weeks prior to screening (daily multivitamin use is
             acceptable).

          -  Glucocorticoid therapy, if used, must have a stable weight-based dose for at least 3
             months prior to enrollment

          -  Cardiac therapy, if used, includes prophylactic ACE inhibitors, aldosterone receptor
             antagonists (e.g.

        spironolactone, eplerenone, etc.), and/or beta-blocker therapy, and must be stable for 3
        months prior to enrollment.

          -  Hematology profile within normal range.

          -  Baseline laboratory safety chemistry profile within typical range for DMD (elevated
             ALT / AST acceptable in the absence of elevated GGT, elevated CK acceptable).

        Exclusion Criteria:

          -  Inability to complete cardiac or strength, range of motion and mobility assessments
             per protocol

          -  Current enrollment in another treatment clinical trial.

          -  History of significant concomitant illness or significant impairment of renal or
             hepatic function.

          -  Use of regular daily aspirin or other medication with antiplatelet effects within 3
             weeks of first dose of study medication.

          -  Cardiac symptoms that, in the opinion of the investigator, may be suggestive of
             imminent moderate to severe cardiac events, irrespective of LVEF.
Clinical trial NCT02967731 (phase 1, status: completed)
Conditions: chronic sinusitis
ICD codes: J32.0, J32.1, J32.2, J32.3, J32.8, J32.9
Drugs: 480 mometasone furoate sinus drug depot
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of CS.

          -  Female study subjects of child-bearing potential must have a negative pregnancy test
             and must agree to not become pregnant during the course of the study.

          -  The study subject has been informed of the nature of the study, agrees to its
             provisions and has provided written informed consent as approved by the ethics
             committee of the respective clinical site.

          -  The study subject agrees to comply with all study requirements

        Exclusion Criteria:

          -  Known history of intolerance to corticosteroids.

          -  Oral-steroid dependent condition.

          -  Having had corticosteroids with potential systemic effect (e.g., oral, parenteral, or
             high dose topical) 1 month prior to screening visit.

          -  Subjects with acute or chronic intracranial or orbital complications of chronic
             rhinosinusitis (e.g., brain abscess, related problems with eyes or central nervous
             system).

          -  Known history of hypothalamic pituitary adrenal (HPA) axial dysfunction or having
             morning serum cortisol level at screening outside of normal range.

          -  Previous pituitary or adrenal surgery.

          -  History or diagnosis (in either eye) of glaucoma, ocular hypertension, or cataracts.

          -  Recent participation in another clinical trial within 1 month of screening visit.

          -  Subjects currently participating in an investigational drug or device study.
Clinical trial NCT02968680 (phase 1, status: terminated)
Conditions: cutaneous melanoma, melanoma
ICD codes: A06.7, A22.0, A26.0, A32.0, A36.3, A43.1, B38.3, C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: sonazoid
SMILES: FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F
Reason stopped: 
    insufficient accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Cutaneous melanoma with Breslow depth > 1 mm or melanoma Breslow depth of 0.76 - 1.00
             mm in setting of ulceration, extensive regression

          -  Mitotic rate >= 1/mm^2

          -  Presence of angiolymphatic invasion

          -  Deep positive margin

          -  No known allergies to contrast material

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Patients with known cardiac shunt

          -  Patients with class II heart failure or worse, per New York Heart Association (NYHA)
             classification

          -  Patients who have experienced an acute coronary syndrome or angina in the past 6
             months

          -  Patients who have undergone coronary artery bypass grafting (CABG) or coronary
             stenting in the past 3 years

          -  Patients with evidence of moderate or severe cardiac valvular disease on
             echocardiogram

          -  Patients with evidence of moderate or severe pulmonary hypertension on echocardiogram

          -  Patients with stage II chronic obstructive pulmonary disease (COPD) or worse, per
             Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification

          -  Patients with hypersensitivity to sonazoid or one of its components

          -  Patients with hypersensitivity to egg or egg products, because sonazoid contains a
             chicken egg-derived surfactant (hydrogenated egg phosphatidylserine sodium)

          -  Patients who cannot consent for themselves
Clinical trial NCT02970032 (early phase 1, status: completed)
Conditions: deep-venous thrombosis, pulmonary embolism, venous thromboembolism
ICD codes: I27.82, Z86.711, I26.01, I26.09, I26.90, I26.99, I26.93, O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: real time heparin dose adjustment, standard heparin dose
SMILES: O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients undergoing surgical procedures

          -  Initiation of a heparin infusion at a rate of 500 units/hour intraoperatively or
             postoperatively

        Exclusion Criteria:

          -  Age <18 years old

          -  Pregnant

          -  Incarcerated

          -  Mentally disabled